XML 29 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Investments Accounted for Using the Equity Method
 6 Months Ended
Jun. 30, 2023
Interests In Other Entities [Abstract]  
Investments Accounted for Using the Equity Method
B.5. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD
Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2022), and comprise:
(€ million)% interestJune 30, 2023December 31, 2022
EUROAPI (a)
29.8 297 392 
Infraserv GmbH & Co. Höchst KG (b)
31.2 88 97 
MSP Vaccine Company (c)
50.0 95 104 
Other investments— 58 84 
Total

538677
(a)As of June 30, 2023, an impairment loss of €91 million euros was recognized on the equity-accounted investment in EUROAPI, given the decrease in the stock market price since March 2023. The amount of the loss was determined based on the stock market price as of June 30, 2023 (€10.50).
(b)Joint venture.
(c)Joint venture MSP Vaccine Company owns 100% of MCM Vaccine BV.

The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:
(€ million)June 30, 2023June 30, 2022December 31, 2022
Sales
64 26131
Royalties and other income
32 3381
Accounts receivable and other receivables
68 110174
Purchases and other expenses (including research expenses)
302 167477
Accounts payable and other payables97 89132